Analytical Data
-
Gene name
MAGEA2
- Application
-
Alternative Names
Cancer/testis antigen 1.2
-
Species
Human
-
Source
E. coli
-
Tag
GST-tag at N-terminal
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P43356
-
Expression Region
1-314aa
-
AA Sequence
MPLEQRSQHCKPEEGLEARGEALGLVGAQAPATEEQQTASSSSTLVEVTL GEVPAADSPSPPHSPQGASSFSTTINYTLWRQSDEGSSNQEEEGPRMFPD LESEFQAAISRKMVELVHFLLLKYQAREPVTKAEMLESVLRNCQDFFPVI FSKASEYLQLVFGIEVVEVVPISHLYILVTCLGLSYDGLLGDNQVMPKTG LLIIVLAIIAIEGDCAPEEKIWEELSMLEVFEGREDSVFAHPRKLLMQDL VQENYLEYRQVPGSDPACYEFLWGPRALIETSYVKVLHHTLKIGGEPHIS YPPLHERALREGEE
-
Molecular Weight
35 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MAGEA2 (Melanoma Antigen Gene A2) is a member of the cancer-testis antigen family, which is primarily expressed in malignant tissues but not in normal somatic tissues, making it an attractive target for cancer immunotherapy. Research on MAGEA2 has gained momentum due to its potential role as a biomarker for various cancers, including melanoma, lung cancer, and bladder cancer. The expression of MAGEA2 is often correlated with tumor progression and poor prognosis, highlighting its significance in the oncological landscape. As a result, scientists have focused on developing recombinant MAGEA2 proteins for use in therapeutic vaccines and diagnostic applications. These recombinant proteins can stimulate the immune system to recognize and attack cancerous cells expressing MAGEA2, promoting tumor regression. Additionally, studies have aimed to elucidate the molecular mechanisms behind MAGEA2 expression and its interactions within the tumor microenvironment. Understanding these mechanisms can provide insights into the development of more effective immunotherapeutic strategies, ultimately improving patient outcomes. As research continues, MAGEA2 may not only serve as a valuable target for cancer treatment but also play a crucial role in personalized cancer therapies, aiding in the design of vaccines tailored to individual patient profiles. The ongoing investigation of MAGEA2 and its recombinant protein forms underscores the importance of exploring novel immunotherapeutic avenues in the fight against cancer.
